Study on transdermal CBD delivery finds positive results

52 0

More evidence supporting the use of CBD to relief chronic health conditions surfaces

One route that may be useful for some patients or users of cannabis is transdermal administration through the skin. A study reveals successful results in the treatment of chronic conditions when cannabidiol (CBD) is applied transdermally. This compound has several routes of administration, and this seems to be one of the most effective for this type of patient.

Evidence-based mental health company Bienestar Digital Sciences Inc. announced that KGK Science, one of its wholly owned subsidiaries, conducted research using Gefion Canada GT4 technology to successfully administer CBD to healthy volunteers in the form of a topical cream applied to the skin. This technology is able to transport CBD through the skin and directly into the blood, thanks to its new penetrating agents. For the first time, the trial showed that the compound was successfully transported into the bloodstream after application to the skin.

As cannabinoids dissolve well in fats due to their lipophilic characteristics, they should theoretically have a lower transdermal penetration capacity than hydrophilic substances. However, cannabinoid preparations are very effective in most cases when applied topically.

They can be used in chronic pathologies, osteoarthritis, fibromyalgia, and rheumatic diseases. Also, preparations rich in CBD have anti-inflammatory and antiproliferative effects, so they are effective in cases of psoriasis and hyperkeratotic dermatitis, or dry eczema.

“These findings present a potential benefit in the treatment of chronic conditions over longer periods of time, or in the treatment of diseases where high concentrations of cannabinoids are needed in relation to the body weight of vulnerable populations such as pediatrics,” per the press release. In addition, the researchers clarified that the administration of CBD proved to be well-tolerated and safe for the participants, with no reported side effects.